How to Get Rezdiffra (Resmetirom) If You Can't Afford It

Why Rezdiffra Costs So Much and What That Actually Means for You

Rezdiffra is the first FDA-approved medication specifically targeting metabolic dysfunction-associated steatohepatitis (MASH), formerly called nonalcoholic steatohepatitis (NASH). As a first-in-class thyroid hormone receptor beta (THR-beta) agonist, it received accelerated approval from the FDA in March 2024 based on surrogate endpoints of liver histology improvement [1]. That novelty drives the pricing.

The wholesale acquisition cost sits near $47,400 annually. Retail cash prices average roughly $3,500 per month depending on pharmacy. These figures sound alarming but represent ceiling prices that few patients actually pay out of pocket. Madrigal has built a multi-layered access infrastructure including copay support, a patient assistance program (PAP), and a dedicated hub called MadrigalConnect.

MASH affects an estimated 6.5 million adults in the United States with fibrosis stages F2 through F4, according to prevalence modeling published in Hepatology [2]. The disease progresses silently and can lead to cirrhosis, liver failure, and hepatocellular carcinoma [3]. Before resmetirom, no pharmacotherapy carried an FDA indication for MASH, leaving clinicians reliant on lifestyle modification and off-label agents. The clinical need is real: the MAESTRO-NASH trial (N=966) demonstrated that resmetirom 80 mg achieved MASH resolution without worsening fibrosis in 25.9% of patients at 52 weeks vs. 9.7% on placebo (P<0.001) [4]. The 100 mg dose performed similarly, with 29.9% achieving MASH resolution vs. 9.7% placebo [4].

Given these outcomes, AASLD practice guidance now positions resmetirom as a treatment option for noncirrhotic MASH with significant fibrosis [5]. Access should not be the barrier.

The Madrigal Copay Assistance Program

Commercially insured patients with a valid Rezdiffra prescription can enroll in Madrigal's copay assistance program, which reduces out-of-pocket costs to as low as $0 per fill for eligible individuals. The program covers the difference between the patient's copay or coinsurance obligation and a preset cap, up to a maximum annual benefit.

Eligibility requirements typically include having commercial (private) insurance, a valid prescription from a licensed prescriber, and U.S. residency. Patients covered under government-funded programs (Medicare Part D, Medicaid, TRICARE, VA) are not eligible for manufacturer copay cards per federal anti-kickback statute constraints [6]. This is standard across the pharmaceutical industry and not unique to Madrigal.

To enroll, patients or prescribers contact MadrigalConnect at the number listed on the Rezdiffra prescribing information or visit the program website directly. The hub performs a benefits investigation, determines the patient's plan-specific copay, and applies the copay card at the pharmacy point of sale. Processing typically takes 5 to 10 business days for initial verification [7].

One practical detail: copay accumulator and maximizer programs used by some pharmacy benefit managers (PBMs) can negate copay card value by preventing manufacturer payments from counting toward the patient's annual deductible or out-of-pocket maximum. The American Journal of Managed Care has documented the growing impact of accumulator programs on specialty drug access [8]. If your plan uses an accumulator adjustment, the copay card may still reduce your immediate cost but will not help you reach your deductible faster. Ask your insurer directly whether your plan applies accumulator or maximizer policies.

The Patient Assistance Program for Uninsured and Underinsured Patients

For patients without insurance or with insurance that denies coverage and leaves no viable appeal pathway, Madrigal offers a patient assistance program providing Rezdiffra at no cost. Income thresholds for PAPs typically fall at or below 400% of the federal poverty level (FPL), which for a single individual in 2026 corresponds to approximately $62,400 annually [9].

Application requires documentation of income (tax returns or pay stubs), proof of U.S. residency, a signed prescription, and a brief prescriber attestation confirming the clinical indication. Turnaround after complete submission averages two to four weeks. Approved patients receive medication shipped directly to their home or prescriber's office, depending on program logistics.

Patients who fall slightly above the income cutoff should still apply. PAP administrators evaluate applications holistically, and high out-of-pocket drug costs relative to household income can sometimes qualify borderline applicants. The FDA's page on patient assistance programs provides a general overview of how manufacturer PAPs work across the industry [10]. Persistence matters. Reapplication after a denial, especially with updated financial documentation, succeeds more often than most patients expect.

Independent Foundations and Copay Assistance Charities

Several nonprofit foundations offer copay grants for liver disease medications. These funds operate independently from Madrigal and can assist patients on Medicare or Medicaid who cannot use manufacturer copay cards. The Patient Access Network (PAN) Foundation, HealthWell Foundation, and the Patient Advocate Foundation have historically funded hepatology-related diagnoses, though specific fund availability for MASH fluctuates with donation cycles [11].

The application process for foundation grants is straightforward. Patients or their providers submit a diagnosis code (K75.81 for MASH), income verification, insurance documentation, and a cost estimate from the pharmacy. Grants are typically time-limited (6 to 12 months) and renewable.

The National Institutes of Health maintains a directory of resources for prescription drug assistance that can help patients identify active funds [12]. Timing is critical: these funds open and close without notice. Prescriber offices with experienced prior authorization staff often monitor fund openings and submit applications within hours of a fund reopening. If your hepatologist's office is unfamiliar with the process, specialty pharmacies that dispense Rezdiffra frequently maintain foundation liaisons.

The NLM's MedlinePlus resource on financial assistance for prescriptions also provides up-to-date links to active programs [13].

Navigating Insurance Coverage and Prior Authorization

Most commercial insurers and Medicare Part D plans require prior authorization (PA) before covering Rezdiffra. The PA process verifies that the patient meets clinical criteria: biopsy-confirmed or noninvasively diagnosed MASH with fibrosis stage F2 or F3, no decompensated cirrhosis, and failure of or contraindication to lifestyle modification alone.

Documentation that strengthens a PA submission includes liver biopsy pathology reports or validated noninvasive test results (FibroScan with CAP, FIB-4 index, or Enhanced Liver Fibrosis [ELF] score), evidence of at least 6 months of dietary and exercise counseling, and relevant lab work including ALT, AST, and lipid panels. The AASLD guidance on noninvasive assessment of liver fibrosis provides the clinical framework that insurers reference when adjudicating these requests [14].

If the initial PA is denied, submit a formal appeal. Include a letter of medical necessity from the prescribing hepatologist or gastroenterologist citing the MAESTRO-NASH trial data: the 100 mg dose produced a ≥1-stage fibrosis improvement without MASH worsening in 25.9% of patients vs. 14.2% on placebo [4]. Reference the FDA approval letter and the drug's status as the only approved pharmacotherapy for this indication [1].

External review, available in most states after an internal appeal denial, involves an independent review organization (IRO) evaluating the clinical evidence. The Centers for Medicare and Medicaid Services (CMS) outlines the appeals process for Medicare beneficiaries on its official site [15]. For commercial plans, state insurance department complaint processes add another layer of recourse. Win rates on external review for specialty drugs with strong clinical evidence and no therapeutic alternatives tend to be favorable.

Step Therapy and Formulary Tier Workarounds

Some PBMs place Rezdiffra on specialty tiers with 25% to 33% coinsurance, or impose step therapy requiring trial and failure of off-label agents like pioglitazone or vitamin E before approving resmetirom. Neither pioglitazone nor vitamin E carries an FDA indication for MASH, though both have been studied in randomized trials [16].

When challenging step therapy requirements, emphasize that resmetirom is the only FDA-approved therapy for MASH and that off-label alternatives carry distinct safety profiles. Pioglitazone is associated with weight gain averaging 2.5 to 4.7 kg and increased fracture risk in postmenopausal women [17]. High-dose vitamin E (800 IU/day) raised concerns about increased all-cause mortality in a meta-analysis published in the Annals of Internal Medicine [18]. These are not equivalent therapeutic options.

The Endocrine Society's clinical practice guidelines on NAFLD/MASH management provide additional clinical context supporting thyroid hormone receptor-targeted therapy as a distinct mechanistic approach [19]. Formulary exception requests citing this differentiation can bypass step therapy mandates.

Documenting contraindications to step therapy agents (e.g., heart failure for pioglitazone, coagulopathy for vitamin E) provides the strongest basis for an exception. Even relative contraindications or tolerability concerns should be documented in the letter of medical necessity.

Specialty Pharmacy Logistics and Refill Planning

Rezdiffra is dispensed through specialty pharmacies, not standard retail pharmacies. Madrigal's distribution network includes both large national specialty pharmacies and select independent specialty pharmacies. MadrigalConnect can direct patients to in-network pharmacies that coordinate benefits, copay card application, and home delivery.

Plan refill timing carefully. Specialty pharmacies typically initiate outreach 7 to 10 days before the next fill date. Supply disruptions, while uncommon, are more impactful for specialty medications with limited distribution. Maintaining a relationship with a single specialty pharmacy simplifies records, benefits coordination, and clinical monitoring.

Hepatic function monitoring during treatment is recommended per the FDA-approved prescribing label. The Rezdiffra prescribing information specifies monitoring hepatic function tests at baseline, during dose titration, and periodically thereafter [7]. Keeping lab work current ensures no interruption in prescription renewal or insurance reauthorization.

Patients receiving medication through the PAP should track reauthorization deadlines. Most PAPs require annual renewal with updated income documentation. Letting authorization lapse creates gaps in supply that are difficult to backfill. Set a calendar reminder 60 days before the expiration date printed on your approval letter.

What If You Have Medicare or Medicaid?

Medicare Part D covers Rezdiffra, but placement on specialty tiers means beneficiaries face the coverage gap (the "donut hole"). Under the Inflation Reduction Act provisions fully effective in 2025, Medicare Part D out-of-pocket spending is capped at $2,000 annually [20]. This cap applies to all covered Part D drugs combined, making Rezdiffra more accessible to Medicare beneficiaries than it would have been under the prior benefit structure.

For Medicaid enrollees, coverage varies by state. Medicaid programs must cover FDA-approved drugs that the manufacturer participates in the Medicaid Drug Rebate Program for, though states can impose preferred drug lists and prior authorization [21]. If your state Medicaid plan denies coverage, request a fair hearing. Medicaid fair hearing rights are federally guaranteed under 42 CFR § 431.200.

Low-Income Subsidy (LIS, also called "Extra Help") significantly reduces Part D cost-sharing for Medicare beneficiaries with limited income and resources. Patients with income below 150% FPL may qualify for full LIS benefits, reducing copays to $0 for generic drugs and small copays for brands [20]. Check eligibility through the Social Security Administration or your State Health Insurance Assistance Program (SHIP).

Dual-eligible patients (those with both Medicare and Medicaid) generally face the lowest out-of-pocket costs and should work with their prescriber to ensure PA requirements for both programs are met simultaneously.

The Clinical Case for Persistence in Seeking Access

Abandoning a Rezdiffra prescription due to cost concerns is common but avoidable. A study in the Journal of Managed Care & Specialty Pharmacy found that up to 40% of specialty prescriptions are never filled due to cost-related barriers [22]. For MASH specifically, disease progression from F2/F3 fibrosis to cirrhosis carries enormous downstream costs: a modeling study in Hepatology estimated lifetime costs of MASH-related cirrhosis at over $95,000 per patient [23].

The MAESTRO-NASH trial also showed meaningful improvements in secondary endpoints. The 100 mg dose reduced LDL cholesterol by approximately 16%, apolipoprotein B by 19%, and triglycerides by 20% compared to placebo at 52 weeks [4]. Given the high cardiovascular comorbidity burden in MASH patients, these lipid effects carry clinical weight. A meta-analysis in The Lancet Gastroenterology & Hepatology confirmed the bidirectional relationship between MASH and cardiovascular disease [24].

Resmetirom's effect on hepatic fat reduction was also substantial: the 100 mg dose achieved a relative reduction in hepatic fat fraction of approximately 53% at week 52 as measured by MRI-PDFF [4]. The FDA's decision to grant accelerated approval cited both fibrosis improvement and MASH resolution endpoints [1]. Confirmatory trials are ongoing, with MAESTRO-NASH continuing to evaluate long-term clinical outcomes.

Every week spent navigating access is worth the effort relative to the alternative of untreated fibrosis progression. Patients who engage MadrigalConnect, file appeals systematically, and apply to foundations concurrently (not sequentially) reduce time-to-fill most effectively.

A Step-by-Step Access Checklist

The fastest path to affordable Rezdiffra follows this sequence. First, have your prescriber submit a benefits investigation through MadrigalConnect. This reveals your plan's formulary status, tier, PA requirements, and projected copay within 5 to 10 business days [7]. Second, file the prior authorization with full documentation simultaneously. Do not wait for the benefits investigation to complete before submitting PA paperwork to the insurer.

Third, if commercially insured, enroll in the copay card program while PA is pending. The card activates upon PA approval. Fourth, if uninsured or underinsured, submit the PAP application with income documentation. Fifth, apply to at least two independent foundations (PAN Foundation, HealthWell) in parallel. Sixth, if PA is denied, appeal within the plan's stated deadline, typically 30 to 60 days. Seventh, if the internal appeal is denied, request external review [15].

Total elapsed time from prescription to first fill averages 2 to 6 weeks for commercially insured patients with straightforward PA approval, and 3 to 8 weeks for PAP applicants. The NIH's NIDDK provides patient education resources on MASH that can help patients understand their diagnosis while navigating access [25].

Do not let sticker shock at the list price prevent you from starting this process. The majority of patients end up paying $0 to $200 per month after all assistance layers are applied.